Menu
Search
|

Menu

Close
X

Edge Therapeutics Inc EDGE.OQ (NASDAQ Stock Exchange Global Select Market)

0.83 USD
-- (--)
As of Oct 17
chart
Previous Close 0.83
Open --
Volume --
3m Avg Volume 61,722
Today’s High --
Today’s Low --
52 Week High 17.76
52 Week Low 0.70
Shares Outstanding (mil) 30.85
Market Capitalization (mil) 340.91
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.078
FY17
-2.108
FY16
-1.345
FY15
-1.900
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.69
Price to Sales (TTM)
vs sector
--
5.82
Price to Book (MRQ)
vs sector
4.04
4.89
Price to Cash Flow (TTM)
vs sector
--
22.95
Total Debt to Equity (MRQ)
vs sector
23.99
17.15
LT Debt to Equity (MRQ)
vs sector
20.32
12.73
Return on Investment (TTM)
vs sector
-43.75
14.30
Return on Equity (TTM)
vs sector
-48.11
16.03

EXECUTIVE LEADERSHIP

Sol Barer
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Brian Leuthner
President, Chief Executive Officer, Director, Since
Salary: $500,000.00
Bonus: --
Isaac Blech
Independent Vice Chairman of the Board, Since 2013
Salary: --
Bonus: --
Andrew Saik
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
W. Bradford Middlekauff
Senior Vice President, General Counsel, Secretary, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

300 Connell Dr Ste 4000
BERKELEY HEIGHTS   NJ   07922-2817

Phone:

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company's product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company's product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

SPONSORED STORIES